Korro Bio (KRRO) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $15.00 | Oct 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 | Aug 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $20.00 | May 19, 2026 |
| Citigroup | Initiated Coverage | Buy | $21.00 | May 18, 2026 |
| Raymond James | Upgraded | Market Perform → Outperform | $23.00 | Mar 13, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $22.00 from $21.00 | Mar 13, 2026 |
| Clear Street | Upgraded | Hold → Buy | $18.00 from $10.00 | Feb 19, 2026 |
| William Blair | Upgraded | Market Perform → Outperform | — | Feb 17, 2026 |
| Piper Sandler | Upgraded | Neutral → Overweight | $30.00 from $11.00 | Jan 29, 2026 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $20.00 | Jan 29, 2026 |
| Chardan Capital | Upgraded | Neutral → Buy | $15.00 from $7.00 | Jan 29, 2026 |
| Cantor Fitzgerald | Upgraded | Neutral → Overweight | $21.00 | Jan 28, 2026 |
| Oppenheimer | Upgraded | Perform → Outperform | $22.00 | Jan 28, 2026 |
| Jones Trading | Downgraded | Buy → Hold | — | Nov 14, 2025 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Nov 13, 2025 |
| Chardan Capital | Downgraded | Buy → Neutral | $7.00 from $25.00 | Nov 13, 2025 |
| Cantor Fitzgerald | Downgraded | Overweight → Neutral | — | Nov 13, 2025 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $8.00 from $85.00 | Nov 13, 2025 |
| William Blair | Downgraded | Outperform → Market Perform | — | Nov 13, 2025 |
| Clear Street | Initiated Coverage | Buy | $93.00 | Oct 31, 2025 |
Frequently asked questions
Is KRRO a buy, sell, or hold?
Analysts covering Korro Bio currently average a Buy rating: 11 buy, 1 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on KRRO?
On Oct 6, 2026, HC Wainwright & Co. maintained Korro Bio at Buy with a price target of $15.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.